Curanex Pharmaceuticals Inc (CURX) 财务

Curanex Pharmaceuticals, Inc. engages in the pharmaceutical business. The company is headquartered in Jericho, New York. The company went IPO on 2025-08-26. The firm is engaged in discovering, developing, and commercializing botanical drugs to treat patients suffering from inflammatory diseases and to develop therapies that offer potential benefits to patients with unmet clinical needs in various fields, such as autoimmune diseases, metabolic diseases and viral infections. Its lead candidate, Phyto-N, is a botanical extract from a single plant with anti-inflammatory properties that act via multiple targets and mechanisms. Its drug development pipelines encompass six various therapeutic areas: ulcerative colitis, atopic dermatitis, COVID-19, diabetes, NAFLD, and gout. Phyto-N is being developed as an orally administered alternative for patients with moderate to severe ulcerative colitis, aiming to address limitations of current treatments. The firm's two botanical drugs include Veregen (sinecatechins) and Fulyzaq/Mytesi (crofelemer).